Monkeypox virus

FDA Grants Emergency Use Authorization for Thermo Fisher Scientific’s Monkeypox Test

Retrieved on: 
Wednesday, December 14, 2022
Science, Other Science, Biotechnology, Pharmaceutical, Medical Supplies, Health, FDA, Infectious Diseases, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Severe acute respiratory syndrome coronavirus 2, PPD, Food, Mindful Scientific Inc., Monkeypox, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Patient, DNA, Science, Patheon, Research, PCR, Pharmaceutical Services Negotiating Committee, Polymerase chain reaction, FDA, Monkeypox virus, Applied Biosystems, COVID-19, Genetic, EUA, Health, Vaccine, Orthopoxvirus

Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit, a polymerase chain reaction (PCR) test designed to detect non-variola Orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit, a polymerase chain reaction (PCR) test designed to detect non-variola Orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours.
  • Ensuring that all U.S. laboratories have access to monkeypox PCR testing is a critical part of the response to this public health emergency, said Manoj Gandhi, senior medical director for Genetic Testing Solutions, Thermo Fisher Scientific.
  • In early 2020, Thermo Fisher was among the first companies to distribute an emergency use authorized assay to identify active SARS-CoV-2 infections with the TaqPath COVID-19 Combo Kit .
  • For Emergency Use Authorization Only; Rx Only
    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

Shineco, Inc. Attends MEDICA 2022 Düsseldorf Germany

Retrieved on: 
Tuesday, November 29, 2022
Marketing, COVID-19, Monkeypox virus, Attention, CBP, Drug Quality and Security Act, Textile, Security (finance), MEDICA, News, SISI, Medical device

MEDICA 2022 is one of the world's largest medical trade fair held annually for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.

Key Points: 
  • MEDICA 2022 is one of the world's largest medical trade fair held annually for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals.
  • With an exhibition area of more than 108,000 square meters, the trade fair attracts visitors and exhibitors from approximately 70 countries worldwide.
  • The CBP team demonstrated its competitive strengths to experts, scholars, and partners in the field of medical testing globally.
  • Utilizing modern engineering technologies and biotechnologies, Shineco produces, among other products, Chinese herbal medicines, organic agricultural produce, and specialized textiles.

2022 Monkeypox Testing Market Research Report - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 23, 2022
Infectious Diseases, Health, Medical Devices, FDA, Hospital, Stanford University School of Medicine, Government, Clifton Springs Hospital & Clinic, PCR, CDC, Viral Research and Diagnostic Laboratories, Monkeypox virus, USD, Research, Monkeypox, FA, Disease, Physiology, Growth, Diagnosis, Incidence, Medical device, Renewable energy, Vaccine

The "Monkeypox Testing Market Size, Share & Trends Analysis Report by Technology (PCR, FA), by End-use (Hospitals & Clinics, Diagnostic Laboratories), by Region (Europe, North America), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Monkeypox Testing Market Size, Share & Trends Analysis Report by Technology (PCR, FA), by End-use (Hospitals & Clinics, Diagnostic Laboratories), by Region (Europe, North America), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global monkeypox testing market size is expected to reach USD 2.63 million by 2030, expanding at a CAGR of 4.35% from 2022 to 2030
    The industry growth is attributed to the increasing incidence of monkeypox cases along with the population growth concerns for the occurrence of another pandemic worldwide.
  • Moreover, government initiatives to increase testing are propelling the growth of the market.
  • Chapter 1 Monkeypox Testing Market: Methodology And Scope
    Chapter 2 Monkeypox Testing Market: Executive Summary
    Chapter 3 Monkeypox Testing Market: Industry Outlook
    3.2 Penetration & Growth Prospect Mapping for monkeypox testing, 2022

Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology

Retrieved on: 
Thursday, November 17, 2022
Adult, Chicago Innovation Awards, Monkeypox virus, FreeStyle, VR, PCR, Center for Food Safety and Applied Nutrition, Federal Food, Drug, and Cosmetic Act, EUA, Infection, COVID-19, CTA, Chronic pain, Ageing, Safety, FDA, Consumer Technology Association, NYSE, Severe acute respiratory syndrome coronavirus 2, Patient, Artificial intelligence, Consumer Electronics Show, Virus, Diabetes, Life, The Economist, Diagnosis, Engineering, Protein, Continuous glucose monitor, Digital health, Comparison, CES, Laboratory, Medical device, Consumer electronics, Vaccine, Pharmaceutical industry, Orthopoxvirus

Ahead of the CES 2023 event, three of Abbott's industry-leading tech advancements won CES 2023 Innovation Awards , all within the Digital Health award category:

Key Points: 
  • Ahead of the CES 2023 event, three of Abbott's industry-leading tech advancements won CES 2023 Innovation Awards , all within the Digital Health award category:
    Aveir VR Leadless Pacemaker Theworld's only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and designed to be completely retrievable.
  • The CES Innovation Awards program is an annual competition honoring outstanding design and engineering in consumer technology products.
  • Last year, Abbott became the first-ever healthcare company to keynote CES, and the company has received nine CES Innovation Awards in the past two years.
  • In addition to the CES 2023 awards, Abbott also was recently recognized with other top honors for its healthcare technology including its revolutionary FreeStyle Libre technology being named the best medical technology in the last 50 years by the Galien Foundation.

Labroots Announces 13th Annual Clinical Diagnostics & Research Virtual Event to be held on November 9th, 2022

Retrieved on: 
Thursday, November 3, 2022
Pathology, PCR, Medical laboratory, Monkeypox, Solution, Melissa Chaty, Risk, COVID-19, Time, Autoantibody, SUC, Research, Monkeypox virus, Science Publishing Group, Drug resistance, Method, ART, QIAGEN, Labroots, IIM, Science, Learning, University of Toronto, Classification, LR, Mount Sinai Hospital, Assistant professor, Social, Environment, Thermo Fisher Scientific, University, Q&A, Severe acute respiratory syndrome coronavirus 2, Precision medicine, Medical device, Pharmaceutical industry, Vaccine, Online shopping, News, Facebook, Clinical

YORBA LINDA, Calif., Nov. 3, 2022   /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, today announced its 13th annual Clinical Diagnostics & Research virtual event. On November 9th, an audience comprised of clinicians, research scholars, top scientists, academia and industry professionals and pharma and biotech will gather under a virtual roof to learn from recognized speakers driving innovation in diagnostics and precision medicine.

Key Points: 
  • Leading experts will explore advancements and new technologies in clinical diagnosis for early disease detection, treatment and prevention during this free, online event
    YORBA LINDA, Calif., Nov. 3, 2022 /PRNewswire-PRWeb/ -- Labroots , the leading scientific social networking website offering premier, interactive virtual events and webinars, today announced its 13th annual Clinical Diagnostics & Research virtual event.
  • For over a decade, this online event has served as a premier meeting place for the clinical diagnostics, research and laboratory medicine communities.
  • And, once again Labroots' Clinical Diagnostics & Research 2022 will deliver on its commitment of breaking science in the areas of emerging diagnostic technologies, perspectives on SARS-CoV-2 and Monkeypox, precision medicine and special populations, and the lab's role in advancing equity.
  • Now, Labroots offers more than ever with Chati, a flexible, highly scalable event platform that allows for the creation of unique, effective, and memorable virtual events.

COMMUNITY EDUCATION GROUP RECEIVES 100K GRANT FOR MONKEYPOX CARE THROUGHOUT RURAL APPALACHIA

Retrieved on: 
Monday, October 31, 2022
Gender identity, Fluid mechanics, Death, Health, ViiV Healthcare, Gilead Sciences, World, Physician, Research, Journal, Heterosexuality, White House, HIV, Patient, Gay, Risk, GLOBE, Organization, Public health, CEG, COVID, COVID-19, Review, World Health Organization, Social change, Monkeypox virus, Education, Pharmaceutical industry, Healthcare, Hospital, Medicine, Vaccine, Monkeypox

With COVID, HIV, Hep-C and, now, Monkeypox, our LBTBQIA+ communities and their health providers in Appalachia need our support now more than ever.

Key Points: 
  • With COVID, HIV, Hep-C and, now, Monkeypox, our LBTBQIA+ communities and their health providers in Appalachia need our support now more than ever.
  • In response to the national public health emergency, Community Education Group launched a new Appalachian Partnership Fund grant geared towards community groups who need financial help to continue their efforts in healthcare education around Monkeypox, said Young.
  • Young said access to healthcare is challenging for many in rural communities, especially for rural LGBTQIA+ individuals living in Appalachia.
  • Community Education Group (CEG) works to eliminate disparities in health outcomes and improve public health in disadvantaged populations and under-served communities.

Keep Your Home Sparkling Clean and EverGREEN This Winter with Shaklee's Proven, Effective, and Environmentally Conscious Get Clean® Germ Off+ Wipes and Basic H2® Cleaner

Retrieved on: 
Monday, October 31, 2022
People, Love, Residential colleges of Yale University, Disinfectant, Safety, Salmonella enterica, Multimedia, Virus, Shigella dysenteriae, World Economic Forum, Solution, CEO, University council, Bacteria, Escherichia coli, Listeria monocytogenes, Klebsiella pneumoniae, Midwest Universities Consortium for International Activities, Harvard University, Germ, Harvard Business School, Staphylococcus aureus, Monkeypox virus, Yale University, Yale Law School, Carbon, Yale College, Element, COVID-19, CDC, Health, Dry cleaning, Vaccine, Salmonella, Instagram, Facebook, Shaklee, Norovirus

Shaklee's Basic H2 Biodegradable Cleaner and Get Clean Germ Off+ Wipes are safe for you, your home, and the planet.

Key Points: 
  • Shaklee's Basic H2 Biodegradable Cleaner and Get Clean Germ Off+ Wipes are safe for you, your home, and the planet.
  • These powerful products clean and disinfect every room of the house, and Germ Off+ Wipes can even be used on food contact surfaces with no rinse required.
  • And Shaklee's leading seller Basic H2 Biodegradable Cleaner is a super safe, powerful all-purpose cleaning concentrate.
  • "We want every household to become "green" by swapping out common, chemical-laden products for our proven and effective Germ Off+ Wipes and Basic H2 cleaner.

Shineco, Inc. to Acquire Controlling Equity Interest in Changzhou Biowin Pharmaceutical Co., Ltd to Step into Point-of-Care Testing Industry

Retrieved on: 
Tuesday, October 25, 2022
SISI, Time, Terminology, Marketing, Securities Act of 1933, Securities Exchange Act of 1934, Company, Peking Union Medical College, News, Test, COVID-19 testing, Patent, U.S. Securities and Exchange Commission, Health, R, NASDAQ, Infection, Power-on self-test, GLOBE, Patient, Population, Prognosis, Degenerative disease, CEO, Guideline, International, Sputum, Ageing, Acquisition, IVD, Industry, COVID-19, EUA, Point-of-care testing, Awareness, Non-functional testing, Security (finance), Dartmouth College, LAMP, Efficiency, Myocardial infarction, Monkeypox, Diabetes, Income, Monkeypox virus, Textile, Saliva, CBP, Leadership, Fine chemical, Medical device, Pharmaceutical industry, EU, POCT

The total amount of this transaction exceeds US$10 million, to be paid in cash and the Companys common stock.

Key Points: 
  • The total amount of this transaction exceeds US$10 million, to be paid in cash and the Companys common stock.
  • This acquisition is a critical initiative of the Company's business strategy of stepping into the Point-of-Care Testing (POCT) industry.
  • In 2021, the market share of IVD was US$117 billion globally, and POCT ranked first in terms of market size, accounting for 29%.
  • As a pioneer in the POCT industry, CBP focuses on the R&D, production and sales of innovative rapid diagnostic products and related medical devices for the most common diseases.

Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication

Retrieved on: 
Wednesday, October 26, 2022
National Institute, Monkeypox virus, Molnupiravir, Ribavirin, Illinois Institute of Technology, Lazzaro Spallanzani National Institute for Infectious Diseases, Omicron, Disease, Risk, Phases of clinical research, Caco-2, IND, Infection, HKEX, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, Investigational New Drug, NHC, Permeability, Monkeypox, WHO, Food, World, Orthopoxvirus, Sofosbuvir, Degenerative disease, Mefloquine, Region (Europe), CEO, Patent, IIT Research Institute, BioRxiv, World Health Organization, FDA, COVID-19, Atovaquone, Pharmaceutical industry, Vaccine, Technology

HANGZHOU and SHAOXING, China, Oct. 26, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the Investigational New Drug (IND) application of ASC10, an oral antiviral drug candidate targeting viral polymerase of monkeypox virus, has been filed with the U.S. Food and Drug Administration (FDA).

Key Points: 
  • ASC10 is an orally bioavailable and broad antiviral spectrum double prodrug which has a new and differentiated chemical structure from the single prodrug molnupiravir.
  • Ascletis has filed multiple patent applications globally for ASC10 and its use in viral diseases including monkeypox virus infection.
  • The data from the in vitro antiviral cellular assay with infectious monkeypox virus demonstrated that ASC10-A has potent antiviral activity against monkeypox virus, suggesting that ASC10 has the potential to be an effective treatment of monkeypox virus infection.
  • This IND filing of ASC10 for monkeypox in the U.S. will further broaden Ascletis' pipeline portfolio in viral diseases, and may provide a solution to monkeypox virus infections."

mergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox

Retrieved on: 
Tuesday, October 18, 2022
Monkeypox virus, Smallpox, Zoonosis, Pox, Disease, Fluid mechanics, Virus, Infection, Vaccine, Poxviridae, GMP, Laboratory, Society, Survivor, Severe acute respiratory syndrome coronavirus 2, Intelligence, Monkeypox, Entrepreneurship, Gastroenterology, Severe cognitive impairment, Scar, Construct, World, Kinetics, CEO, World Health Organization, Vaccination, DNA, Peptide, Death, MedRxiv, DG, HLA

The monkeypox virus is part of the same family of double-stranded DNA viruses (Poxviridae) as variola virus, the virus that causes smallpox; they share many highly conserved proteins that make ideal T cell vaccine targets.

Key Points: 
  • The monkeypox virus is part of the same family of double-stranded DNA viruses (Poxviridae) as variola virus, the virus that causes smallpox; they share many highly conserved proteins that make ideal T cell vaccine targets.
  • The fact that the vaccine constructs pathogen peptides come from the eclipse phase of viral replication plays a key role in infection kinetics.
  • Phillip Williams, Chief Scientific Officer at Emergex commented: Were very proud to have synthesized this smallpox and monkeypox vaccine so quickly using intelligence and resources to target highly conserved sequences shared by both viruses.
  • With a fatality rate of >30% in unvaccinated people, there are concerns that smallpox could pose a future biosecurity threat.